Last reviewed · How we verify
NCT05107661
Colorectal Screening Strategies in Underserved Populations
trial testing Telephone Prompt in Colorectal Cancer in 62 participants. Terminated before completion.
9 August 2023
Quick facts
| Lead sponsor | Virtua Health, Inc. |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 62 |
| Start date | 26 September 2021 |
| Primary completion | 9 August 2023 |
| Estimated completion | 9 August 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Telephone Prompt
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
Sponsor
Virtua Health, Inc. — full company profile →
Who can join
Adults 45 to 64, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Research efforts are necessary to identify strategies to increase colorectal screening in underserved patient populations. Racial, ethnic minorities and medically underserved individuals continue to experience disparities in colorectal cancer mortality despite the availability of screening tests that can detect tumors early when treatments are most effective.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05107661
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other Virtua Health, Inc. trials
Trials by the same sponsor.
- NCT05704842 — Evaluate Impact of Exercise Program on Fatigue in Breast Cancer During Chemotherapy · NA · recruiting
- NCT05107687 — Effectiveness of Smoking Cessation Program in a Community Health System · unknown
- NCT05522153 — Arista Hemostatic Powder for Total Knee Post Operative Outcomes Study · Phase 1 · completed
- NCT03523897 — A Prospective Study to Evaluate Robot Assisted Total Knee Replacement Outcomes · NA · terminated
- NCT03276026 — A Study to Compare Neostigmine vs Sugammadex in Length of PACU Stay in Patients Undergoing Sleeve Gastrectomy Surgery · Phase 4 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05107661 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Virtua Health, Inc.
- Last refreshed: 14 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05107661.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing